Boston Scientific Corp
BSX- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000885725
In the last 90 days, Boston Scientific Corp insiders filed 5 open-market purchases and 0 sales; 1,487 institutions reported holding it in 13F filings for Q2 2026, worth $57.3B in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Boston Scientific Corp as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,151
- +109 vs. Q3 2023
- Shares held
- 1.34B
- +267.4K (0.0%) vs. Q3 2023
- Total value
- $77.3B
- +$6.74B (+9.6%) vs. Q3 2023
- New holders
- 178
- 441 more added
- Sold out
- 69
- 378 more reduced
18 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BSX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,487 | $57.3B |
| Q1 2026 | 1,683 | $84.2B |
| Q4 2025 | 1,793 | $130.0B |
| Q3 2025 | 1,714 | $131.1B |
| Q2 2025 | 1,693 | $145.4B |
| Q1 2025 | 1,648 | $135.2B |
| Q4 2024 | 1,519 | $119.8B |
| Q3 2024 | 1,402 | $111.0B |
| Q2 2024 | 1,324 | $102.2B |
| Q1 2024 | 1,226 | $90.9B |
| Q4 2023 | 1,151 | $77.3B |
| Q3 2023 | 1,060 | $70.6B |
| Q2 2023 | 1,069 | $71.6B |
| Q1 2023 | 1,000 | $65.7B |
| Q4 2022 | 930 | $60.5B |
| Q3 2022 | 866 | $50.9B |
| Q2 2022 | 882 | $48.6B |
| Q1 2022 | 909 | $57.0B |
| Q4 2021 | 892 | $54.8B |
| Q3 2021 | 884 | $56.6B |
| Q2 2021 | 873 | $55.3B |
| Q1 2021 | 836 | $49.9B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Boston Scientific Corp; share changes are against Q3 2023.